CEO Eric Keller Buys $249,600 of Retension Stock at $12.00 on IPO Day
RTSN sits 29% above its 52-week low of $9.66 on light trading volume (0.4× avg).
Summary
CEO Eric Keller bought $249,600 of Retension Pharmaceuticals stock at the $12.00 IPO price on the closing date, a real-money purchase that stands out against the stock's weak post-IPO trading.
Key Events · Ownership and Investor Activity · RTSN
-
CEO Buys $249,600 at IPO Price
CEO Eric L. Keller purchased 20,800 shares at $12.00 per share for $249,600 on 2026-10-13, the IPO closing date — a real-money open-market purchase (Code P).
-
Purchase Above Post-IPO Trading Price
The $12.00 purchase price matches the IPO price, but the stock opened at $10.00 and fell to $10.36 in early trading on 2026-10-09, meaning the CEO paid above where the stock has been trading.
-
Option Grant of 255,174 Shares
CEO received a stock option grant for 255,174 shares with an exercise price of $11.63, vesting 25% on August 14, 2027 and the remainder in 36 monthly installments.
-
Preferred Stock Converts at IPO
9,662 Series A and 31,368 Series B preferred shares converted automatically into common stock immediately prior to the IPO closing, with no consideration paid.
Analysis · RTSN · Life Sciences
CEO Eric Keller put $249,600 of his own money into Retension Pharmaceuticals at the $12.00 IPO price on the closing date — a real-money open-market purchase, not an option exercise or grant. This comes just days after the company's IPO priced at $12.00 but opened at $10.00 and fell nearly 14% in early trading, so the CEO buying at the full IPO price while the stock trades below it is a notable show of conviction. The filing also shows a 255,174-share option grant with a $11.63 strike price and the automatic conversion of 41,030 preferred shares into common stock tied to the IPO closing.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 36.5% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RTSN was trading at $12.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.7M. The 52-week trading range was $9.66 to $12.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.